MedTrace Logo

Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

NCT02890719 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2025-06-22

No results posted yet for this study

Summary

Pilot, single center, open-label study to evaluate the efficacy and tolerability of Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant recipients with hepatitis C recurrence.

Conditions

  • Liver Transplantation
  • Hepatitis C

Interventions

DRUG

Grazoprevir 100 mg/day

Grazoprevir 100 mg/ day 12 weeks

DRUG

Elbasvir 50 mg/d

Elbasvir 50 mg/day 12 weeks

DRUG

Grazoprevir 100 mg/day

Grazoprevir 100 mg/day 16 weeks

DRUG

Elbasvir 50 mg/day

Elbasvir 50 mg/d 16 weeks

DRUG

Ribavirin 1200 mg/day

Ribavirin 1200 mg/day 16 weeks

Sponsors & Collaborators

  • Fundacion Clinic per a la Recerca Biomédica

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-03
Primary Completion
2017-06-01
Completion
2017-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02890719 on ClinicalTrials.gov